<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: We aimed to determine an effective dose schedule for intravenously administered <z:chebi fb="131" ids="25107">magnesium</z:chebi>, to establish its neuroprotective efficacy in both pre- and postischemic treatment paradigms, and to compare the neuroprotective properties of MgSO(4) and MgCl(2) </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: Rats that had been subjected to the bilateral carotid <z:mp ids='MP_0006134'>artery occlusion</z:mp> plus <z:hpo ids='HP_0002615'>hypotension</z:hpo> model of transient forebrain <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> received either an intravenously administered loading dose (LD) of 360 micromol/kg MgSO(4) only or an intravenously administered LD of 360 micromol/kg followed by a 48-hour intravenous infusion of MgSO(4) at either 60, 120, 240, or 480 micromol/kg/h </plain></SENT>
<SENT sid="2" pm="."><plain>For evaluation of the efficacy of MgSO(4) after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, the dose (LD, 360 micromol/kg; infusion, 120 micromol/kg/h) that provided maximal neuroprotection before <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> was administered 4, 8, 12, or 24 hours after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>MgCl(2) (LD, 360 micromol/kg; infusion, 120 micromol/kg/h) was administered before and 8 hours after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>At 7 days after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, hippocampal CA1 neurons were histologically examined for protection </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Animals that received the LD only demonstrated 33% hippocampal CA1 neuronal survival </plain></SENT>
<SENT sid="6" pm="."><plain>Animals that received the LD followed by continuous infusion of MgSO(4) at either 60, 120, 240, or 480 micromol/kg/h demonstrated 30, 80, 16, and less than 5% CA1 neuronal survival, respectively </plain></SENT>
<SENT sid="7" pm="."><plain>MgSO(4) treatment commencing at 4, 8, 12, or 24 hours resulted in 82, 71, 52, and 33% CA1 neuronal survival, respectively </plain></SENT>
<SENT sid="8" pm="."><plain>Preischemic and 8-hour postischemic administration of MgCl(2) resulted in 50% and less than 5% CA1 neuronal survival, respectively </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSION: These results demonstrate a neuroprotective intravenous dose of MgSO(4), which is effective when administered before or late after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, and a previously uncharacterized dose-response curve for MgSO(4) </plain></SENT>
</text></document>